Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
NCT06355310
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG:
Empagliflozin 10 MG
DRUG:
Placebo Oral Tablet
Sponsor
Justin Ryder